Research News
Ovarian Cancer Canada funds research into prevention, improved treatments, and ultimately a cure. Science continues to uncover new knowledge that impacts treatment and survival. Here’s how.
A champion for women living with ovarian cancer, Pat McDonald has done everything from co-chairing the Ovarian Cancer Canada Walk of Hope to serving on our Board of Directors to leading Knowledge is Power and Survivors Teaching Students® awareness sessions. A veritable force of nature, she has attended nearly every event in and around Halifax, gathering a faithful following over the years.
Women living with ovarian cancer and their families recently had the opportunity to hear directly from scientists as part of a session called “Ovarian Cancer Research and You.” This special presentation was held in conjunction with the 8th Canadian Conference on Ovarian Cancer Research, which convened leading minds in the field.
Ovarian Cancer Canada alongside GOC wishes to congratulate the members of the research team for translating ongoing research on the connection between fallopian tubes and ovarian cancer into clinical practice.
Ovarian Cancer Canada is a proud program collaborator in the exciting Terry Fox Research Institute (TFRI) initiative that seeks to change how ovarian cancer is diagnosed and managed worldwide.
People who financially support the cause of overcoming ovarian cancer – “the most lethal women’s cancer” – have a “moderate to high donor opportunity for impact,” according to a recent research report by Charity Intelligence Canada (Ci).
We are pleased to announce the recipients of the 2012 Ovarian Cancer Canada Teal Heart Scholarships.
Up to 80% of Canadians with cancer use complementary medicine (CAM) during their cancer experience.
Why do some women with ovarian cancer survive longer than others who are diagnosed with this deadly disease?
Dr. Andrea Krawczyk believes passionately in helping people learn about preventing cancer.
Adding bevacizumab (Avastin) to standard chemotherapy delays disease progression in patients with difficult-to-treat recurrent ovarian cancer.